VRTX — Vertex Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $112.92bn
- $105.68bn
- $12.00bn
Brief: Vertex Pharmaceuticals Q1 Revenue USD 2,760.2 Million Vs. IBES Estimate USD 2,853 Million
Analysis: Trump health policy uncertainty sends biotech sector into deeper slump
Brief: Vertex Researcher, Paul Negulescu Ph.D., Receives The 2025 Canada Gairdner International Award For Pioneering Research And Discovery Of Medicines For Cystic Fibrosis
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
U.S. STOCKS ON THE MOVE-Fractyl Health, Keurig Dr Pepper, PVH
RBC raises Vertex PT, expects strong start for cystic fibrosis drug
Brief: Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing
Brief: Vertex Announces Program Updates For Type 1 Diabetes Portfolio
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy
Focus: Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty
Brief: Vertex Announces UK Mhra Approval Of Alyftrek
Brief: UK's MHRA Approves Triple Combination Of Deutivacaftor/Tezacaftor/Vanzacaftor For Cystic Fibrosis
Status of Vertex's painkiller on UnitedHealth lists poses modest challenge, BMO says
Brief: Vertex Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group
Vertex falls after Q4 profit, sales of gene therapy disappoint